Guanhao Biotech Co Ltd (300238) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.037x

Based on the latest financial reports, Guanhao Biotech Co Ltd (300238) has a cash flow conversion efficiency ratio of 0.037x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥18.84 Million ≈ $2.76 Million USD) by net assets (CN¥506.03 Million ≈ $74.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300238 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Guanhao Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Guanhao Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guanhao Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guanhao Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Nawi Brothers Group Ltd
TA:NAWI
-0.714x
Daqian Ecology & Landscape Co Ltd
SHG:603955
-0.030x
Spin Master Corp
TO:TOY
0.044x
Johnson Outdoors Inc
NASDAQ:JOUT
-0.093x
Shanghai Information2 Software Inc. A
SHG:688435
N/A
Groupe Guillin SA
PA:ALGIL
0.100x
Hes Technology Group
SHE:002963
0.058x
Pacific Biosciences of California
NASDAQ:PACB
-18.889x

Annual Cash Flow Conversion Efficiency for Guanhao Biotech Co Ltd (2007–2025)

The table below shows the annual cash flow conversion efficiency of Guanhao Biotech Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300238 market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥506.03 Million
≈ $74.05 Million
CN¥71.47 Million
≈ $10.46 Million
0.141x +33.28%
2024-12-31 CN¥467.59 Million
≈ $68.42 Million
CN¥49.55 Million
≈ $7.25 Million
0.106x -10.70%
2023-12-31 CN¥456.26 Million
≈ $66.77 Million
CN¥54.15 Million
≈ $7.92 Million
0.119x -27.96%
2022-12-31 CN¥430.88 Million
≈ $63.05 Million
CN¥70.98 Million
≈ $10.39 Million
0.165x +0.70%
2021-12-31 CN¥748.16 Million
≈ $109.48 Million
CN¥122.39 Million
≈ $17.91 Million
0.164x +12.91%
2020-12-31 CN¥716.66 Million
≈ $104.87 Million
CN¥103.84 Million
≈ $15.19 Million
0.145x +10.24%
2019-12-31 CN¥704.14 Million
≈ $103.04 Million
CN¥92.55 Million
≈ $13.54 Million
0.131x +370.53%
2018-12-31 CN¥1.16 Billion
≈ $169.08 Million
CN¥32.28 Million
≈ $4.72 Million
0.028x +76.29%
2017-12-31 CN¥1.21 Billion
≈ $177.49 Million
CN¥19.22 Million
≈ $2.81 Million
0.016x -24.74%
2016-12-31 CN¥1.46 Billion
≈ $213.26 Million
CN¥30.68 Million
≈ $4.49 Million
0.021x -80.75%
2015-12-31 CN¥620.62 Million
≈ $90.82 Million
CN¥67.87 Million
≈ $9.93 Million
0.109x -11.18%
2014-12-31 CN¥531.61 Million
≈ $77.79 Million
CN¥65.45 Million
≈ $9.58 Million
0.123x +47.83%
2013-12-31 CN¥498.16 Million
≈ $72.90 Million
CN¥41.49 Million
≈ $6.07 Million
0.083x -23.01%
2012-12-31 CN¥454.11 Million
≈ $66.45 Million
CN¥49.12 Million
≈ $7.19 Million
0.108x +32.06%
2011-12-31 CN¥432.79 Million
≈ $63.33 Million
CN¥35.45 Million
≈ $5.19 Million
0.082x -64.81%
2010-12-31 CN¥144.99 Million
≈ $21.22 Million
CN¥33.76 Million
≈ $4.94 Million
0.233x +222.72%
2009-12-31 CN¥76.95 Million
≈ $11.26 Million
CN¥5.55 Million
≈ $812.33K
0.072x -44.41%
2008-12-31 CN¥37.01 Million
≈ $5.42 Million
CN¥4.80 Million
≈ $702.80K
0.130x +55.21%
2007-12-31 CN¥20.67 Million
≈ $3.02 Million
CN¥1.73 Million
≈ $252.86K
0.084x --

About Guanhao Biotech Co Ltd

SHE:300238 China Biotechnology
Market Cap
$429.13 Million
CN¥2.93 Billion CNY
Market Cap Rank
#13194 Global
#3944 in China
Share Price
CN¥11.06
Change (1 day)
+1.84%
52-Week Range
CN¥10.66 - CN¥19.00
All Time High
CN¥56.32
About

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; T… Read more